TP 4311

Drug Profile

TP 4311

Alternative Names: TP-4311

Latest Information Update: 17 May 2016

Price : $50

At a glance

  • Originator Thetis Pharmaceuticals
  • Developer Thetis Pharmaceuticals; University of Bonn
  • Class Antihyperlipidaemics; Docosahexaenoic acids; Small molecules
  • Mechanism of Action Inflammation mediator inhibitors; Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Postoperative ileus

Most Recent Events

  • 03 May 2016 Preclinical trials in Postoperative ileus in Germany (IV) (Thetis Pharmaceuticals pipeline; May 2016)
  • 03 May 2016 Thetis Pharmaceuticals has a patent pending for TP 4311 in USA (Thetis Pharmaceuticals website; May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top